124O Patritumab deruxtecan (HER3-DXd) in hormonal receptor-positive/HER2-negative (HR+/HER2-) and triple-negative breast cancer (TNBC): Results of part B of SOLTI TOT-HER3 window of opportunity trialMafalda Oliveira, Aleix Prat, F.J. Salvador Bofill et al.|ESMO Open|2023Cited by 8
195P Health-related quality of life outcomes in SOLTI VALENTINE: A trial of neoadjuvant HER3-DXd +/- letrozole for high-risk hormone receptor positive/HER2-negative early breast cancerGuillermo Villacampa, Ana Muntañola Prat, Mikele Praia de Oliveira et al.|ESMO Open|2025Cited by 1
3MO HER2 expression and early response to patritumab deruxtecan (HER3-DXd) in early-stage hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC): A correlative analysis from SOLTI-TOT-HER3 trialFara Brasó‐Maristany, Aleix Prat, Mafalda Oliveira et al.|ESMO Open|2023Cited by 0